Article Text

Download PDFPDF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Coinfeciton with HIV and Mycobacterium tuberculosis is common in sub-Saharan Africa and each infection accelerates the progression of the other. Isoniazid prophylaxis is known to be effective in HIV-infected adults and has now been shown to be effective in children. In Cape Town (BMJ 2007;334:136–9; see also editorial, ibid: 105–6) a randomised trial of isoniazid against placebo for HIV-infected children taking co-trimoxazole was stopped early because of better results in the isoniazid group. A total of 263 children (median age 25 months) had been followed up for an average of 6 months. Mortality and tuberculosis incidence were both significantly lower in the isoniazid group (8% vs 16% and 4% vs 10% respectively). There were no culture-confirmed cases of tuberculosis in the isoniazid group.

In 2001 WHO and UNICEF agreed a plan to halve global measles mortality by the end of 2005, using 1999 as the baseline year. The plan depended on four strategies: high immunisation coverage (>90%) including a second dose when possible, case surveillance, monitoring of immunisation coverage, and appropriate clinical case management including provision of vitamin A. A recent report (Lancet 2007;369:191–200; see also Comment, ibid: 165–6) suggests that the aim has been achieved. The figures for measles mortality are based …

View Full Text